[Complex neuro-ectodermic dysplasia associated with oligophrenia, spastic paraplegia, epilepsy, cataract and congenital ichthyosis. Nosological discussion].

J. Boudouresques,R. Khalil,R. Vigouroux,M. Poncet,J. Bille

1969-04-01

Abstract:

What problem does this paper attempt to address?

Status Report on COVID-19 Vaccines Development

Arun Kumar,William E. Dowling,Raúl Gómez Román,Amol Chaudhari,Celine Gurry,Tung Thanh Le,Stig Tollefson,Carolyn E Clark,Valentina Bernasconi,Paul A Kristiansen

DOI: https://doi.org/10.1007/s11908-021-00752-3

2021-04-14

Current Infectious Disease Reports

Abstract:Abstract Purpose of Review The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. There is an urgent need to develop interventions including vaccines to control the ongoing pandemic. Recent Findings Development of tools for fast-tracked testing including small and large animal models for vaccine efficacy analysis, assays for immunogenicity assessment, critical reagents, international biological standards, and data sharing allowed accelerated development of vaccines. More than 300 vaccines are under development and 9 of them are approved for emergency use in various countries, with impressive efficacy ranging from 50 to 95%. Recently, several new SARS-CoV-2 variants have emerged and are circulating globally, and preliminary findings imply that some of them may escape immune responses against previous variants and diminish efficacy of current vaccines. Most of these variants acquired new mutations in their surface protein (Spike) which is the antigen in most of the approved/under development vaccines. Summary In this review, we summarize novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based. Critical assessment of humoral and cell-mediated immune responses induced by vaccines has shown comparative immunogenicity profiles of various vaccines in clinical phases. Recent reports confirmed that some currently available vaccines provide partial to complete protection against emerging SARS-CoV-2 variants. If more mutated variants emerge, current vaccines might need to be updated accordingly either by developing vaccines matching the circulating strain or designing multivalent vaccines to extend the breadth.

infectious diseases
COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Jasmine R Marcelin,Audrey Pettifor,Holly Janes,Elizabeth R Brown,James G Kublin,Kathryn E Stephenson

DOI: https://doi.org/10.1093/ofid/ofac124

2022-03-10

Open Forum Infectious Diseases

Abstract:Abstract Coronavirus disease 2019 (COVID-19) vaccines have yielded definitive prevention and major reductions in morbidity and mortality from severe acute respiratory syndrome coronavirus 2 infection, even in the context of emerging and persistent variants of concern. Newer variants have revealed less vaccine protection against infection and attenuation of vaccine effects on transmission. COVID-19 vaccines still likely reduce transmission compared with not being vaccinated at all, even with variants of concern; however, determining the magnitude of transmission reduction is constrained by the challenges of performing these studies, requiring accurate linkage of infections to vaccine status and timing thereof, particularly within households. In this review, we synthesize the currently available data on the impact of COVID-19 vaccines on infection, serious illness, and transmission; we also identify the challenges and opportunities associated with policy development based on this data.

immunology,infectious diseases,microbiology
Challenges and Recent Advancements in COVID-19 Vaccines

Shao-Cheng Wang,Chung-I Rai,Yuan-Chuan Chen

DOI: https://doi.org/10.3390/microorganisms11030787

IF: 4.5

2023-03-18

Microorganisms

Abstract:Vaccination is the most effective method for the prevention of COVID-19 caused by SARS-CoV-2, which is still a global epidemic. However, the evolution of SARS-CoV-2 is so rapid that various variants, including the Alpha, Beta, Gamma, Delta, and Omicron variants, have emerged, lowering the protection rate of vaccines and even resulting in breakthrough infections. Additionally, some rare but severe adverse reactions induced by COVID-19 vaccines may raise safety concerns and hinder vaccine promotion; however, clinical studies have shown that the benefits of vaccination outweigh the risks caused by adverse reactions. Current vaccines approved with emergency use authorization (EUA) were originally adaptive for adults only, and infants, children, and adolescents are not included. New-generation vaccines are needed to overcome the challenges of limited adaptive age population, breakthrough infection (mainly due to virus variant emergencies), and critical adverse reactions. Fortunately, some advances in COVID-19 vaccines have been obtained regarding enlarged adaptive populations for clinical applications, such as the Pfizer/BioNTech vaccine and the Moderna vaccine. In this article, we provide a review on the challenges and recent advancements in COVID-19 vaccines. The development of next-generation COVID-19 vaccines should lay emphasis on the expansion of adaptive age populations in all individuals, the induction of immune responses to viral variants, the avoidance or alleviation of rare but potentially critical adverse reactions, and the discovery of subunit vaccines with adjuvants encapsulated in nanoparticles.

microbiology
COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Narjess Bostanghadiri,Pardis Ziaeefar,Morvarid Golrokh Mofrad,Parsa Yousefzadeh,Ali Hashemi,Davood Darban-Sarokhalil

DOI: https://doi.org/10.1155/2023/1879554

2023-08-30

BioMed Research International

Abstract:The world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are focused on developing and manufacturing standard treatment strategies and effective vaccines to control the pandemic. Despite developing several vaccines such as Pfizer/BioNTech and Moderna approved by the U.S. Food and Drug Administration (FDA) and other vaccines in phase 4 clinical trials, preventive measures are mandatory to control the COVID-19 pandemic. In this review, based on the latest findings, we will discuss different types of drugs as therapeutic options and confirmed or developing vaccine candidates against SARS-CoV-2. We also discuss in detail the challenges posed by the variants and their effect on therapeutic and preventive interventions.

biotechnology & applied microbiology,medicine, research & experimental
SARS-CoV-2 Vaccine Development: Current Status

Gregory A Poland,Inna G Ovsyannikova,Stephen N Crooke,Richard B Kennedy,Gregory A. Poland,Inna G. Ovsyannikova,Stephen N. Crooke,Richard B. Kennedy

DOI: https://doi.org/10.1016/j.mayocp.2020.07.021

IF: 11.104

2020-10-01

Mayo Clinic Proceedings

Abstract:<p>In the midst of the SARS-CoV-2 pandemic and its attendant morbidity and mortality, safe and efficacious vaccines are needed that induce protective and long-lived immune responses. Over 120 vaccine candidates worldwide are in various preclinical, and phase I-III clinical trials that include inactivated, live attenuated, viral vectored replicating and non-replicating), protein and peptide-based, and nucleic acid approaches. Vaccines will be necessary both for individual protection and for the safe development of population-level herd immunity. Public-private partnership collaborative efforts, such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) mechanism, are key to rapidly identifying safe and effective vaccie candidates as quickly and efficiently as possible. In this article, we review the major vaccine approaches being taken and issues that must be resolved in the quest for vaccines to prevent COVID-19.</p><p>We scanned the PubMed database from 1963–2020 for all publications using the following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2, vaccine, clinical trial, coronavirus, pandemic, vaccine development. We also did a web search for these same terms. We also examined the World Health Organization, Centers for Disease Control and Prevention, and other public health authority websites. We excluded abstracts and all articles that were not written in English.</p>

medicine, general & internal
An overview of vaccine development for COVID-19

Seyed H Shahcheraghi,Jamshid Ayatollahi,Alaa AA Aljabali,Madhur D Shastri,Shakti D Shukla,Dinesh K Chellappan,Niraj K Jha,Krishnan Anand,Naresh K Katari,Meenu Mehta,Saurabh Satija,Harish Dureja,Vijay Mishra,Abdulmajeed G Almutary,Abdullah M Alnuqaydan,Nitin Charbe,Parteek Prasher,Gaurav Gupta,Kamal Dua,Marzieh Lotfi,Hamid A Bakshi,Murtaza M Tambuwala

DOI: https://doi.org/10.4155/tde-2020-0129

2021-03-01

Therapeutic Delivery

Abstract:The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines – peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus – are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
Scope of SARS-CoV-2 variants, mutations, and vaccine technologies

Josephine Wambani,Patrick Okoth

DOI: https://doi.org/10.1186/s43162-022-00121-z

Abstract:Background: The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is disseminated by respiratory aerosols. The virus uses the spike protein to target epithelial cells by binding to the ACE2 receptor on the host cells. As a result, effective vaccines must target the viral spike glycoprotein. However, the appearance of an Omicron variant with 32 mutations in its spike protein raises questions about the vaccine's efficacy. Vaccines are critical in boosting immunity, lowering COVID-19-related illnesses, reducing the infectious burden on the healthcare system, and reducing economic loss, according to current data. An efficient vaccination campaign is projected to increase innate and adaptive immune responses, offering better protection against SARS-CoV-2 variants. Main body: The presence of altered SARS-CoV-2 variants circulating around the world puts the effectiveness of vaccines already on the market at risk. The problem is made even worse by the Omicron variant, which has 32 mutations in its spike protein. Experts are currently examining the potential consequences of commercial vaccines on variants. However, there are worries about the vaccines' safety, the protection they provide, and whether future structural changes are required for these vaccines to be more effective. As a result of these concerns, new vaccines based on modern technology should be developed to guard against the growing SARS-CoV-2 variations. Conclusion: The choice of a particular vaccine is influenced by several factors including mode of action, storage conditions, group of the vaccinee, immune response mounted, cost, dosage protocol, age, and side effects. Currently, seven SARS-CoV-2 vaccine platforms have been developed. This comprises of inactivated viruses, messenger RNA (mRNA), DNA vaccines, protein subunits, nonreplicating and replicating vector viral-like particles (VLP), and live attenuated vaccines. This review focuses on the SARS-CoV-2 mutations, variants of concern (VOCs), and advances in vaccine technologies.
A modification to the technique of lesser-curve myotomy.

W. S. Walker,T. Taylor

1982-03-01

Annals of The Royal College of Surgeons of England

Abstract:A simple, quick modification to the technique of lesser-curve myotomy is described and its advantages discussed.
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Wei-Yu Chi,Yen-Der Li,Hsin-Che Huang,Timothy En Haw Chan,Sih-Yao Chow,Jun-Han Su,Louise Ferrall,Chien-Fu Hung,T.-C. Wu

DOI: https://doi.org/10.1186/s12929-022-00853-8

2022-10-16

Journal of Biomedical Science

Abstract:Coronavirus Disease 2019 (COVID-19) has been the most severe public health challenge in this century. Two years after its emergence, the rapid development and deployment of effective COVID-19 vaccines have successfully controlled this pandemic and greatly reduced the risk of severe illness and death associated with COVID-19. However, due to its ability to rapidly evolve, the SARS-CoV-2 virus may never be eradicated, and there are many important new topics to work on if we need to live with this virus for a long time. To this end, we hope to provide essential knowledge for researchers who work on the improvement of future COVID-19 vaccines. In this review, we provided an up-to-date summary for current COVID-19 vaccines, discussed the biological basis and clinical impact of SARS-CoV-2 variants and subvariants, and analyzed the effectiveness of various vaccine booster regimens against different SARS-CoV-2 strains. Additionally, we reviewed potential mechanisms of vaccine-induced severe adverse events, summarized current studies regarding immune correlates of protection, and finally, discussed the development of next-generation vaccines.

cell biology,medicine, research & experimental
Development of SARS-CoV-2 Vaccine: Challenges and Prospects

Tooba Mahboob,Amni Adilah Ismail,Muhammad Raza Shah,Mohammed Rahmatullah,Maria de Lourdes Pereira,Christophe Wiart,Polrat Wilairatana,Mogana Rajagopal,Veeranoot Nissapatorn,Alok K. Paul,Karma G. Dolma

DOI: https://doi.org/10.3390/diseases11020064

2023-04-20

Diseases

Abstract:The WHO declared coronavirus disease 2019 (COVID-19) a pandemic in March 2020, which was caused by novel coronavirus severe acute respiratory coronavirus 2 (SARS-CoV-2). SARS-CoV-2 made its first entry into the world in November 2019, and the first case was detected in Wuhan, China. Mutations in the SARS-CoV-2 genome distressed life in almost every discipline by the extended production of novel viral variants. In this article, authorized SARS-CoV-2 vaccines including mRNA vaccines, DNA vaccines, subunit vaccines, inactivated virus vaccines, viral vector vaccine, live attenuated virus vaccines and mix and match vaccines will be discussed based on their mechanism, administration, storage, stability, safety and efficacy. The information was collected from various journals via electronic searches including PubMed, Science Direct, Google Scholar and the WHO platform. This review article includes a brief summary on the pathophysiology, epidemiology, mutant variants and management strategies related to COVID-19. Due to the continuous production and unsatisfactory understanding of novel variants of SARS-CoV-2, it is important to design an effective vaccine along with long-lasting protection against variant strains by eliminating the gaps through practical and theoretical knowledge. Consequently, it is mandatory to update the literature through previous and ongoing trials of vaccines tested among various ethnicities and age groups to gain a better insight into management strategies and combat complications associated with upcoming novel variants of SARS-CoV-2.
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu M. Bennet,Jayanthi Wolf,Rodrigo Laureano,Rani S. Sellers

DOI: https://doi.org/10.1177/0192623320959090

2020-09-14

Toxicologic Pathology

Abstract:The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an urgent need to develop safe and efficacious vaccines. The scientific community has made tremendous efforts to understand the disease, and unparalleled efforts are ongoing to develop vaccines and treatments. Toxicologists and pathologists are involved in these efforts to test the efficacy and safety of vaccine candidates. Presently, there are several SARS-CoV-2 vaccines in clinical trials, and the pace of vaccine development has been highly accelerated to meet the urgent need. By 2021, efficacy and safety data from clinical trials are expected, and potentially a vaccine will be available for those most at risk. This review focuses on the ongoing SARS-CoV-2 vaccine development efforts with emphasis on the nonclinical safety assessment and discusses emerging preliminary data from nonclinical and clinical studies. It also provides a brief overview on vaccines for other coronaviruses, since experience gained from these can be useful in the development of SARS-CoV-2 vaccines. This review will also explain why, despite this unprecedented pace of vaccine development, rigorous standards are in place to ensure nonclinical and clinical safety and efficacy. [Box: see text]

pathology,toxicology
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

Tanmay Ghildiyal,Nishant Rai,Janhvi Mishra Rawat,Maargavi Singh,Jigisha Anand,Gaurav Pant,Gaurav Kumar,Amrullah Shidiki

DOI: https://doi.org/10.1155/2024/9125398

IF: 4.4929

2024-01-26

Journal of Immunology Research

Abstract:Since the COVID-19 outbreak, the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus has evolved into variants with varied infectivity. Vaccines developed against COVID-19 infection have boosted immunity, but there is still uncertainty on how long the immunity from natural infection or vaccination will last. The present study attempts to outline the present level of information about the contagiousness and spread of SARS-CoV-2 variants of interest and variants of concern (VOCs). The keywords like COVID-19 vaccine types, VOCs, universal vaccines, bivalent, and other relevant terms were searched in NCBI, Science Direct, and WHO databases to review the published literature. The review provides an integrative discussion on the current state of knowledge on the type of vaccines developed against SARS-CoV-2, the safety and efficacy of COVID-19 vaccines concerning the VOCs, and prospects of novel universal, chimeric, and bivalent mRNA vaccines efficacy to fend off existing variants and other emerging coronaviruses. Genomic variation can be quite significant, as seen by the notable differences in impact, transmission rate, morbidity, and death during several human coronavirus outbreaks. Therefore, understanding the amount and characteristics of coronavirus genetic diversity in historical and contemporary strains can help researchers get an edge over upcoming variants.

immunology
COVID-19 Variants and Vaccine Development

Ziyao Zhao,Sahra Bashiri,Zyta M. Ziora,Istvan Toth,Mariusz Skwarczynski

DOI: https://doi.org/10.3390/v16050757

2024-05-11

Viruses

Abstract:Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and fatalities worldwide. Extensive SARS-CoV-2 research has been conducted to develop therapeutic drugs and prophylactic vaccines, and even though some drugs have been approved to treat SARS-CoV-2 infection, treatment efficacy remains limited. Therefore, preventive vaccination has been implemented on a global scale and represents the primary approach to combat the COVID-19 pandemic. Approved vaccines vary in composition, although vaccine design has been based on either the key viral structural (spike) protein or viral components carrying this protein. Therefore, mutations of the virus, particularly mutations in the S protein, severely compromise the effectiveness of current vaccines and the ability to control COVID-19 infection. This review begins by describing the SARS-CoV-2 viral composition, the mechanism of infection, the role of angiotensin-converting enzyme 2, the host defence responses against infection and the most common vaccine designs. Next, this review summarizes the common mutations of SARS-CoV-2 and how these mutations change viral properties, confer immune escape and influence vaccine efficacy. Finally, this review discusses global strategies that have been employed to mitigate the decreases in vaccine efficacy encountered against new variants.

virology
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Monika Kumari,Ruei-Min Lu,Mu-Chun Li,Jhih-Liang Huang,Fu-Fei Hsu,Shih-Han Ko,Feng-Yi Ke,Shih-Chieh Su,Kang-Hao Liang,Joyce Pei-Yi Yuan,Hsiao-Ling Chiang,Cheng-Pu Sun,I.-Jung Lee,Wen-Shan Li,Hsing-Pang Hsieh,Mi-Hua Tao,Han-Chung Wu

DOI: https://doi.org/10.1186/s12929-022-00852-9

2022-09-13

Journal of Biomedical Science

Abstract:The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains.

cell biology,medicine, research & experimental
Current Updates on COVID-19 Vaccines and Therapeutics: As of June 2022

Wooseong Lee,Seong-Jun Kim

DOI: https://doi.org/10.1007/s12257-022-0188-4

Abstract:Since COVID-19, caused by SARS-CoV-2 infection, has become a global issue, many vaccines and therapeutic candidates have been developed or are being developed against the COVID-19 endemic and the next wave. However, it is difficult to overcome the spread and mutation rate of SARS-CoV-2 in the COVID-19 pandemic because development of vaccines and therapeutics involves considerable social cost and time, as well as research capabilities. Thus, assessing the development status of these agents is important for advancing efficient research strategies. In this review, we summarize the status of 141 vaccines and 345 therapeutic candidates under development worldwide, according to their development stage and characteristics. As of June 2022, 32 vaccines and 12 therapeutics have been approved for emergency use. Although the development of four of these therapeutics was terminated owing to their low efficacy against various variants of SARS-CoV-2, many new candidates that have completed phase 3 clinical trials have been awaiting phase 4 clinical trials or full approval by the Food and Drug Administration (FDA). These efforts are expected to contribute to establishing an efficient research strategy to overcome the COVID-19 pandemic and facilitate its transition toward an endemic phase. Electronic supplementary material esm: The online version of this article (doi: 10.1007/s12257-022-0188-4) contains supplementary material, which is available to authorized users.
Platforms Exploited for SARS-CoV-2 Vaccine Development

Shilu Mathew,Muhammed Faheem,Neeraja A. Hassain,Fatiha M. Benslimane,Asmaa A. Al Thani,Hassan Zaraket,Hadi M. Yassine

DOI: https://doi.org/10.3390/vaccines9010011

2020-12-25

Vaccines

Abstract:The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only zoonotic-origin coronavirus (CoV) that has reached the pandemic stage. The virus uses its spike (S) glycoprotein to attach to the host cells and initiate a cascade of events that leads to infection. It has sternly affected public health, economy, education, and social behavior around the world. Several scientific and medical communities have mounted concerted efforts to limit this pandemic and the subsequent wave of viral spread by developing preventative and potential vaccines. So far, no medicine or vaccine has been approved to prevent or treat coronavirus disease 2019 (COVID-19). This review describes the latest advances in the development of SARS-CoV-2 vaccines for humans, mainly focusing on the lead candidates in clinical trials. Moreover, we seek to provide both the advantages and the disadvantages of the leading platforms used in current vaccine development, based on past vaccine delivery efforts for non-SARS CoV-2 infections. We also highlight the population groups who should receive a vaccine against COVID-19 in a timely manner to eradicate the pandemic rapidly.

immunology,medicine, research & experimental
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Cole J Batty,Mark T Heise,Eric M Bachelder,Kristy M Ainslie

DOI: https://doi.org/10.1016/j.addr.2020.12.006

Abstract:The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented effort toward the development of an effective and safe vaccine. Aided by extensive research efforts into characterizing and developing countermeasures towards prior coronavirus epidemics, as well as recent developments of diverse vaccine platform technologies, hundreds of vaccine candidates using dozens of delivery vehicles and routes have been proposed and evaluated preclinically. A high demand coupled with massive effort from researchers has led to the advancement of at least 31 candidate vaccines in clinical trials, many using platforms that have never before been approved for use in humans. This review will address the approach and requirements for a successful vaccine against SARS-CoV-2, the background of the myriad of vaccine platforms currently in clinical trials for COVID-19 prevention, and a summary of the present results of those trials. It concludes with a perspective on formulation problems which remain to be addressed in COVID-19 vaccine development and antigens or adjuvants which may be worth further investigation.
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

Dona Susan Mathew,Tirtha Pandya,Het Pandya,Yuzen Vaghela,Selvakumar Subbian

DOI: https://doi.org/10.3390/biom13111565

IF: 6.064

2023-10-24

Biomolecules

Abstract:The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology in various internal organs. However, the etiopathogenesis of SARS-CoV-2 infection is not fully understood. Currently, there are no targeted therapies available to cure COVID-19, and most patients are treated empirically with anti-inflammatory and/or anti-viral drugs, based on the disease symptoms. Although several types of vaccines are currently implemented to control COVID-19 and prevent viral dissemination, the emergence of new variants of SARS-CoV-2 that can evade the vaccine-induced protective immunity poses challenges to current vaccination strategies and highlights the necessity to develop better and improved vaccines. In this review, we summarize the etiopathogenesis of SARS-CoV-2 and elaborately discuss various types of vaccines and vaccination strategies, focusing on those vaccines that are currently in use worldwide to combat COVID-19 or in various stages of clinical development to use in humans.
Insulin-like growth factor-1 modulates steroid hormone effects on osteocalcin synthesis in human MG-63 osteosarcoma cells.

A. Pirskanen,T. Jääskeläinen,P. Mäenpää

DOI: https://doi.org/10.1111/J.1432-1033.1993.TB18444.X

1993-12-01

European Journal of Biochemistry

Abstract:The 1,25-dihydroxyvitamin-D3-(calcitriol)-induced medium osteocalcin and cellular osteocalcin mRNA concentrations are increased in a dose-dependent and time-dependent manner by prior treatment of the human MG-63 osteosarcoma cells with insulin-like growth factor-I (IGF-I). In addition, IGF-I reverses the inhibitory effects of dexamethasone and enhances the effects of retinoic acid on osteocalcin synthesis. The stimulatory effect of IGF-I on osteocalcin synthesis is accompanied by stabilization of osteocalcin mRNA and a decrease of AP-1 binding to the osteocalcin promoter. The binding of the vitamin-D receptor (VDR) to its cognate response element is not affected by IGF-I. In contrast to its effects on osteocalcin synthesis, both baseline and calcitriol-stimulated alkaline phosphatase activities are decreased by IGF-I treatment. Furthermore, IGF-I has mitogenic effects on MG-63 cells. The proliferation of the cells and the levels of c-jun mRNA are greatly increased during IGF-I treatment. Calcitriol reduces or eliminates both these effects. The low concentrations of IGF-I used in this study suggest that IGF-I is an important normal regulator of the synthesis of osteocalcin, a bone calcium-binding protein participating in bone mineralization, by modulating the effects of steroid hormones on its synthesis.
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

DOI: https://doi.org/10.1007/s40265-024-02013-8

2024-04-24

Drugs

Abstract:The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to the World Health Organization (WHO). Leveraging rapid development, accelerated vaccine approval processes, and large-scale production of various COVID-19 vaccines using different technical platforms, the WHO declared an end to the global health emergency of COVID-19 on May 5, 2023. Current COVID-19 vaccines encompass inactivated, live attenuated, viral vector, protein subunit, nucleic acid (DNA and RNA), and virus-like particle (VLP) vaccines. However, the efficacy of these vaccines is diminishing due to the constant mutation of SARS-CoV-2 and the heightened immune evasion abilities of emerging variants. This review examines the impact of the COVID-19 pandemic, the biological characteristics of the virus, and its diverse variants. Moreover, the review underscores the effectiveness, advantages, and disadvantages of authorized COVID-19 vaccines. Additionally, it analyzes the challenges, strategies, and future prospects of developing a safe, broad-spectrum vaccine that confers sufficient and sustainable immune protection against new variants of SARS-CoV-2. These discussions not only offer insight for the development of next-generation COVID-19 vaccines but also summarize experiences for combating future emerging viruses.

pharmacology & pharmacy,toxicology

[Complex neuro-ectodermic dysplasia associated with oligophrenia, spastic paraplegia, epilepsy, cataract and congenital ichthyosis. Nosological discussion].

Status Report on COVID-19 Vaccines Development

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Challenges and Recent Advancements in COVID-19 Vaccines

COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

SARS-CoV-2 Vaccine Development: Current Status

An overview of vaccine development for COVID-19

Scope of SARS-CoV-2 variants, mutations, and vaccine technologies

A modification to the technique of lesser-curve myotomy.

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Development of SARS-CoV-2 Vaccine: Challenges and Prospects

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

COVID-19 Variants and Vaccine Development

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Current Updates on COVID-19 Vaccines and Therapeutics: As of June 2022

Platforms Exploited for SARS-CoV-2 Vaccine Development

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

Insulin-like growth factor-1 modulates steroid hormone effects on osteocalcin synthesis in human MG-63 osteosarcoma cells.

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines